18F-FDG PET/CT对接受风险适应免疫化疗方案治疗的弥漫性大B细胞淋巴瘤的预后价值
该研究分析了166例接受风险适应免疫化疗的弥漫性大B细胞淋巴瘤(DLBCL)患者,在基线、中期和疗程结束时行18F-FDG PET/CT。中位随访7.9年,基线代谢肿瘤体积(MTV)和中期最大SUV变化率(ΔSUVmax)可预测无进展生存(PFS)和总生存(OS),中期Deauville评分联合ΔSUVmax可能识别极高危人群。
要点
- 基线MTV和中期ΔSUVmax是PFS和OS的显著预测因素。
- 中期Deauville 4-5且ΔSUVmax≤70%者(约10%)预后极差。
- IMPI在本队列中区分能力有限且轻微高估事件率。
核心结论
- 基线MTV和中期ΔSUVmax可预测该序贯免疫化疗方案下的PFS和OS。
- 中期Deauville评分联合中期ΔSUVmax可能识别极高危DLBCL人群。
研究设计与样本
- 分析166例接受风险适应免疫化疗方案的DLBCL患者的18F-FDG PET/CT预后价值。
- 基线、4周期R-CHOP或3周期RR-CHOP(双倍剂量R)加1周期CHOP后(中期)及治疗结束后6周(EOT)行PET/CT。
- 采用Kaplan-Meier法估计PFS和OS,Cox模型评估临床/PET因素的影响,并评估IMPI的预测能力。
主要发现
- 中位随访7.9年。
- 国际预后指数(IPI)、基线MTV和中期ΔSUVmax是OS的统计学显著预测因素。
- 基线MTV、中期ΔSUVmax和EOT Deauville评分是PFS的统计学显著预测因素。
- 中期Deauville 4-5且ΔSUVmax≤70%者(约10%队列)预后极差。
- IMPI在本队列中区分能力有限且轻微高估事件率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early identification of patients with diffuse large B-cell lymphoma (DLBCL) who are likely to experience disease recurrence or refractory disease after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) would be useful for improving risk-adapted treatment strategies. We aimed to assess the prognostic value of 18F-FDG PET/CT parameters at baseline, interim, and end of treatment (EOT). Methods: We analyzed the prognostic impact of 18F-FDG PET/CT in 166 patients with DLBCL treated with a risk-adapted immunochemotherapy regimen. Scans were obtained at baseline, after 4 cycles of R-CHOP or 3 cycles of RR-CHOP (double dose of R) and 1 cycle of CHOP alone (interim) and 6 wk after completing therapy (EOT). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier and the impact of clinical/PET factors assessed with Cox models. We also assessed the predictive ability of the recently proposed International Metabolic Prognostic Index (IMPI). Results: The median follow-up was 7.9 y. International Prognostic Index (IPI), baseline metabolic tumor volume (MTV), and change in maximum SUV (ΔSUVmax) at interim scans were statistically significant predictors for OS. Baseline MTV, interim ΔSUVmax, and EOT Deauville score were statistically significant predictors of PFS. Combining interim PET parameters demonstrated that patients with Deauville 4-5 and positive ΔSUVmax ≤ 70% at restaging (∼10% of the cohort) had extremely poor prognosis. The IMPI had limited discrimination and slightly overestimated the event rate in our cohort. Conclusion: Baseline MTV and interim ΔSUVmax predicted both PFS and OS with this sequential immunochemotherapy program. Combining interim Deauville score with interim ΔSUVmax may identify an extremely high-risk DLBCL population.
引用
- Michaud L, Bantilan K, Mauguen A, et al. Prognostic Value of 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen. J Nucl Med. 2022. PMID: 36549918. doi:10.2967/jnumed.122.264740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。